In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model.

Abstract

F-L-DNR can effectively target FR(+) leukemia cells in vivo. Further preclinical evaluation is warranted to determine its potential application in leukemia therapy.